Johnson & Johnson Protagonist Therapeutics, Inc Transaction History
Johnson & Johnson
- $290 Million
- Q2 2024
A detailed history of Johnson & Johnson transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Johnson & Johnson holds 2,449,183 shares of PTGX stock, worth $112 Million. This represents 29.31% of its overall portfolio holdings.
Number of Shares
2,449,183
Previous 2,449,183
-0.0%
Holding current value
$112 Million
Previous $70.9 Million
19.77%
% of portfolio
29.31%
Previous 14.92%
Shares
1 transactions
Others Institutions Holding PTGX
# of Institutions
195Shares Held
58.7MCall Options Held
20.8KPut Options Held
109K-
Farallon Capital Management LLC San Francisco, CA5.84MShares$268 Million0.98% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$264 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.29MShares$243 Million3.06% of portfolio
-
Bvf Inc San Francisco, CA3.32MShares$152 Million3.52% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.24MShares$149 Million0.0% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $2.25B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...